上市暴涨90%，华方资本投出了国内TCE领域第一股

Core Viewpoint - The article highlights the successful IPO of Nanjing Weili Zhizhi Biotechnology Co., Ltd. on the Hong Kong Stock Exchange, emphasizing the long-term investment strategy and support from Huafang Capital throughout the company's development journey [1][3]. Group 1: Company Overview - Nanjing Weili Zhizhi Biotechnology, founded in 2012, focuses on discovering, developing, and commercializing new therapies for tumors, autoimmune diseases, and other major diseases [3]. - The company became the first stock in the TCE (T-cell Engager) field in China, backed by top-tier institutions including Morgan Stanley and CITIC Securities, with cornerstone subscriptions exceeding half of the total issuance [3]. Group 2: Investment Journey - Huafang Capital's initial investment in Weili Zhizhi in 2018 marked a significant turning point, as the company was still in the pre-clinical stage at that time [4]. - In 2019, Huafang Capital, along with its parent company, led a new round of investment totaling 200 million yuan to help Weili Zhizhi navigate through a critical phase of development [5]. Group 3: Market Performance - On its first day of trading on July 25, 2025, Weili Zhizhi's stock opened at 72.4 HKD per share, reaching a peak of 79.6 HKD, with a maximum increase of 127.43%, and closing at 67.1 HKD, reflecting a 91.71% rise, resulting in a market capitalization of 12.97 billion HKD [1][3]. Group 4: Huafang Capital's Strategy - Established in 2017, Huafang Capital specializes in early-stage investments in high-end manufacturing, biomedicine, and new-generation information technology, leveraging its extensive industry and capital operation experience [6]. - The firm emphasizes post-investment empowerment and has formed a strategic layout targeting leading companies in niche sectors [6].